Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 3:1-14.
doi: 10.3171/2022.12.PEDS22282. Online ahead of print.

Magnetic resonance imaging-guided stereotactic laser ablation therapy for the treatment of pediatric epilepsy: a retrospective multiinstitutional study

Affiliations

Magnetic resonance imaging-guided stereotactic laser ablation therapy for the treatment of pediatric epilepsy: a retrospective multiinstitutional study

Elsa V Arocho-Quinones et al. J Neurosurg Pediatr. .

Abstract

Objective: The authors of this study evaluated the safety and efficacy of stereotactic laser ablation (SLA) for the treatment of drug-resistant epilepsy (DRE) in children.

Methods: Seventeen North American centers were enrolled in the study. Data for pediatric patients with DRE who had been treated with SLA between 2008 and 2018 were retrospectively reviewed.

Results: A total of 225 patients, mean age 12.8 ± 5.8 years, were identified. Target-of-interest (TOI) locations included extratemporal (44.4%), temporal neocortical (8.4%), mesiotemporal (23.1%), hypothalamic (14.2%), and callosal (9.8%). Visualase and NeuroBlate SLA systems were used in 199 and 26 cases, respectively. Procedure goals included ablation (149 cases), disconnection (63), or both (13). The mean follow-up was 27 ± 20.4 months. Improvement in targeted seizure type (TST) was seen in 179 (84.0%) patients. Engel classification was reported for 167 (74.2%) patients; excluding the palliative cases, 74 (49.7%), 35 (23.5%), 10 (6.7%), and 30 (20.1%) patients had Engel class I, II, III, and IV outcomes, respectively. For patients with a follow-up ≥ 12 months, 25 (51.0%), 18 (36.7%), 3 (6.1%), and 3 (6.1%) had Engel class I, II, III, and IV outcomes, respectively. Patients with a history of pre-SLA surgery related to the TOI, a pathology of malformation of cortical development, and 2+ trajectories per TOI were more likely to experience no improvement in seizure frequency and/or to have an unfavorable outcome. A greater number of smaller thermal lesions was associated with greater improvement in TST. Thirty (13.3%) patients experienced 51 short-term complications including malpositioned catheter (3 cases), intracranial hemorrhage (2), transient neurological deficit (19), permanent neurological deficit (3), symptomatic perilesional edema (6), hydrocephalus (1), CSF leakage (1), wound infection (2), unplanned ICU stay (5), and unplanned 30-day readmission (9). The relative incidence of complications was higher in the hypothalamic target location. Target volume, number of laser trajectories, number or size of thermal lesions, or use of perioperative steroids did not have a significant effect on short-term complications.

Conclusions: SLA appears to be an effective and well-tolerated treatment option for children with DRE. Large-volume prospective studies are needed to better understand the indications for treatment and demonstrate the long-term efficacy of SLA in this population.

Keywords: drug-resistant epilepsy; functional neurosurgery; laser interstitial thermal therapy; magnetic resonance imaging–guided stereotactic laser ablation; minimally invasive technique; pediatric epilepsy; seizure focus.

PubMed Disclaimer

Conflict of interest statement

Dr. Tovar-Spinoza is a consultant for Monteris. Dr. Smyth is a consultant for and receives personal fees from Monteris, outside the submitted work. Dr. Perry receives personal fees from Zogenix, Stroke Therapeutics, Greenwich Biosciences, Biomarin, Marinus, Taysha, Neurelis, NobelPharma, Eisai, and Bright Minds, outside the submitted work. Dr. Barnett receives personal fees from Monteris Medical outside the submitted work. Dr. Muh receives personal fees from Livanova LLC during the conduct of this study and has a patent for a ventriculoperitoneal shunt. Dr. Thompson is a paid scientific advisor for Oncoheroes Biosciences outside the submitted work.

References

    1. Youngerman BE, Save AV, McKhann GM. Magnetic resonance imaging-guided laser interstitial thermal therapy for epilepsy: systematic review of technique, indications, and outcomes. Neurosurgery. 2020;86(4):E366–E382. - PubMed
    1. Esquenazi Y, Kalamangalam GP, Slater JD, et al. Stereotactic laser ablation of epileptogenic periventricular nodular heterotopia. Epilepsy Res. 2014;108(3):547–554. - PubMed
    1. Landazuri P, Shih J, Leuthardt E, et al. A prospective multicenter study of laser ablation for drug resistant epilepsy—one year outcomes. Epilepsy Res. 2020;167:106473. - PubMed
    1. Xue F, Chen T, Sun H. Postoperative outcomes of magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) in the treatment of drug-resistant epilepsy: a meta-analysis. Med Sci Monit. 2018;24:9292–9299. - PMC - PubMed
    1. Curry DJ, Gowda A, McNichols RJ, Wilfong AA. MR-guided stereotactic laser ablation of epileptogenic foci in children. Epilepsy Behav. 2012;24(4):408–414. - PubMed